Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 31 for:    CTPS1

Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00674960
Recruitment Status : Unknown
Verified August 2009 by GAAD Medical Research Institute Inc..
Recruitment status was:  Active, not recruiting
First Posted : May 8, 2008
Last Update Posted : August 17, 2009
Sponsor:
Information provided by:
GAAD Medical Research Institute Inc.

Tracking Information
First Submitted Date  ICMJE May 6, 2008
First Posted Date  ICMJE May 8, 2008
Last Update Posted Date August 17, 2009
Study Start Date  ICMJE May 2008
Estimated Primary Completion Date May 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 14, 2009)
Therapy for FTD patients [ Time Frame: 1 year ]
Original Primary Outcome Measures  ICMJE
 (submitted: May 7, 2008)
Therapy for FTD patients [ Time Frame: 2 years ]
Change History Complete list of historical versions of study NCT00674960 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 14, 2009)
Rehabilitation of FTD Patients [ Time Frame: 1 Year ]
Original Secondary Outcome Measures  ICMJE
 (submitted: May 7, 2008)
Rehabilitation of FTD Patients [ Time Frame: 2 Years ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia
Official Title  ICMJE Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Management, Control and Treatment of Frontotemporal Dementia (Pick's Disease)
Brief Summary Pick's disease, also known as Pick disease,or FTD is a rare fronto-temporal neurodegenerative disease. This study will investigate the use of far infrared radiation for the control, management and treatment of Pick's disease.
Detailed Description

This disorder causes progressive destruction of nerve cells in the brain and causes tau proteins to accumulate into the "Pick bodies" that are a defining characteristic of the disease. Tau proteins are microtubule-associated proteins that are abundant in neurons in the central nervous system and are less common elsewhere.

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have FTD.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Pick Disease of the Brain
Intervention  ICMJE Radiation: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Other Name: Far Infrared Radiation (5μm to 20μm wavelength)
Study Arms  ICMJE Experimental: 1
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Intervention: Radiation: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Actual Enrollment  ICMJE
 (submitted: August 14, 2009)
0
Original Estimated Enrollment  ICMJE
 (submitted: May 7, 2008)
5
Estimated Study Completion Date  ICMJE October 2009
Estimated Primary Completion Date May 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • People with Pick's Disease

Exclusion Criteria:

  • None
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE Child, Adult, Older Adult
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00674960
Other Study ID Numbers  ICMJE GAAD-FD-CTP1
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party : Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc.
Study Sponsor  ICMJE GAAD Medical Research Institute Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
PRS Account GAAD Medical Research Institute Inc.
Verification Date August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP